These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 36124638)

  • 1. An Indirect Comparison of the Efficacy and Safety of Dostarlimab and Doxorubicin for the Treatment of Advanced and Recurrent Endometrial Cancer.
    Mathews C; Lorusso D; Coleman RL; Boklage S; Garside J
    Oncologist; 2022 Dec; 27(12):1058-1066. PubMed ID: 36124638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes for Dostarlimab and Real-World Treatments in Post-platinum Patients With Advanced/Recurrent Endometrial Cancer: The GARNET Trial Versus a US Electronic Health Record-Based External Control Arm.
    Goulden S; Shen Q; Coleman RL; Mathews C; Hunger M; Pahwa A; Schade R
    J Health Econ Outcomes Res; 2023; 10(2):53-61. PubMed ID: 37701519
    [No Abstract]   [Full Text] [Related]  

  • 3. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm study.
    Oaknin A; Gilbert L; Tinker AV; Brown J; Mathews C; Press J; Sabatier R; O'Malley DM; Samouelian V; Boni V; Duska L; Ghamande S; Ghatage P; Kristeleit R; Leath C III; Guo W; Im E; Zildjian S; Han X; Duan T; Veneris J; Pothuri B
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35064011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of dostarlimab versus chemotherapy in post-platinum patients with recurrent/advanced endometrial cancer: data from the GARNET trial and the National Cancer Registration Service in England.
    Goulden S; Heffernan K; Sen Nikitas F; Shukla U; Knott C; Hunger M; Pahwa A; Schade R
    Int J Gynecol Cancer; 2023 Nov; 33(11):1715-1723. PubMed ID: 37620100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study.
    Oaknin A; Pothuri B; Gilbert L; Sabatier R; Brown J; Ghamande S; Mathews C; O'Malley DM; Kristeleit R; Boni V; Gravina A; Banerjee S; Miller R; Pikiel J; Mirza MR; Dewal N; Antony G; Dong Y; Zografos E; Veneris J; Tinker AV
    Clin Cancer Res; 2023 Nov; 29(22):4564-4574. PubMed ID: 37363992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors: A Nonrandomized Controlled Trial.
    André T; Berton D; Curigliano G; Sabatier R; Tinker AV; Oaknin A; Ellard S; de Braud F; Arkenau HT; Trigo J; Gravina A; Kristeleit R; Moreno V; Abdeddaim C; Vano YA; Samouëlian V; Miller R; Boni V; Torres AA; Gilbert L; Brown J; Dewal N; Dabrowski C; Antony G; Zografos E; Veneris J; Banerjee S
    JAMA Netw Open; 2023 Nov; 6(11):e2341165. PubMed ID: 37917058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical activity and safety of the anti-PD-1 monoclonal antibody dostarlimab for patients with recurrent or advanced dMMR endometrial cancer.
    Oaknin A; Tinker AV; Gilbert L; Samouëlian V; Mathews C; Brown J; Barretina-Ginesta MP; Moreno V; Gravina A; Abdeddaim C; Banerjee S; Guo W; Danaee H; Im E; Sabatier R
    Future Oncol; 2021 Oct; 17(29):3781-3785. PubMed ID: 34427115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer.
    Mirza MR; Chase DM; Slomovitz BM; dePont Christensen R; Novák Z; Black D; Gilbert L; Sharma S; Valabrega G; Landrum LM; Hanker LC; Stuckey A; Boere I; Gold MA; Auranen A; Pothuri B; Cibula D; McCourt C; Raspagliesi F; Shahin MS; Gill SE; Monk BJ; Buscema J; Herzog TJ; Copeland LJ; Tian M; He Z; Stevens S; Zografos E; Coleman RL; Powell MA;
    N Engl J Med; 2023 Jun; 388(23):2145-2158. PubMed ID: 36972026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dostarlimab for the treatment of advanced endometrial cancer.
    Redondo A; Gallego A; Mendiola M
    Expert Rev Clin Pharmacol; 2022 Jan; 15(1):1-9. PubMed ID: 35184615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of dostarlimab in combination with chemotherapy in patients with primary advanced or recurrent endometrial cancer in a phase III, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY).
    Auranen A; Powell MA; Sukhin V; Landrum LM; Ronzino G; Buscema J; Bauerschlag D; Lalisang R; Bender D; Gilbert L; Armstrong A; Safra T; Nevadunsky N; Sebastianelli A; Slomovitz B; Ring K; Coleman R; Podzielinski I; Stuckey A; Teneriello M; Gill S; Pothuri B; Willmott L; Sharma S; Dabrowski C; Antony G; Stevens S; Mirza MR; Fleming E
    Ther Adv Med Oncol; 2024; 16():17588359241277656. PubMed ID: 39346117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world dostarlimab use in advanced/recurrent endometrial cancer in France.
    Rodrigues M; Eberst L; Follana P; Gauthier L; Jacquemin V; Tessier C; El Mouaddin N; Boudier P; Fiteni F; Angeli E; Roche S; Delanoy N; Sabatier R; Flippot R; de la Motte Rouge T
    Bull Cancer; 2023 Oct; 110(10):1041-1050. PubMed ID: 37659907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trial.
    Powell MA; Bjørge L; Willmott L; Novák Z; Black D; Gilbert L; Sharma S; Valabrega G; Landrum LM; Gropp-Meier M; Stuckey A; Boere I; Gold MA; Segev Y; Gill SE; Gennigens C; Sebastianelli A; Shahin MS; Pothuri B; Monk BJ; Buscema J; Coleman RL; Slomovitz BM; Ring KL; Herzog TJ; Balas MM; Grimshaw M; Stevens S; Lai DW; McCourt C; Mirza MR
    Ann Oncol; 2024 Aug; 35(8):728-738. PubMed ID: 38866180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Activity and Safety of the Anti-Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair-Deficient Endometrial Cancer: A Nonrandomized Phase 1 Clinical Trial.
    Oaknin A; Tinker AV; Gilbert L; Samouëlian V; Mathews C; Brown J; Barretina-Ginesta MP; Moreno V; Gravina A; Abdeddaim C; Banerjee S; Guo W; Danaee H; Im E; Sabatier R
    JAMA Oncol; 2020 Nov; 6(11):1766-1772. PubMed ID: 33001143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dostarlimab for recurrent mismatch repair-deficient endometrial cancer: A cost-effectiveness study.
    Dioun S; Chen L; Melamed A; Gockley A; St Clair CM; Hou JY; Khoury-Collado F; Hur C; Elkin E; Accordino M; Hershman DL; Wright JD
    BJOG; 2023 Jan; 130(2):214-221. PubMed ID: 36330672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Budget impact of dostarlimab plus carboplatin-paclitaxel for primary advanced or recurrent endometrial cancer from a third-party US payer perspective.
    Lubinga SJ; Walder L; Burton M; Shen Q
    J Med Econ; 2024; 27(1):1212-1221. PubMed ID: 39254489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient-reported outcomes in the GARNET trial in patients with advanced or recurrent mismatch repair-deficient/microsatellite instability-high endometrial cancer treated with dostarlimab.
    Kristeleit R; Mathews C; Redondo A; Boklage S; Hanlon J; Im E; Brown J
    Int J Gynecol Cancer; 2022 Aug; 32(10):1250-7. PubMed ID: 35973737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dostarlimab in the treatment of mismatch repair deficient recurrent or advanced endometrial cancer.
    Shukla S; Patel H; Chen S; Sun R; Wei L; Chen ZS
    Cancer Pathog Ther; 2024 Jul; 2(3):135-141. PubMed ID: 39027143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient-reported outcomes in the subpopulation of patients with mismatch repair-deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO/GOG3031/RUBY trial.
    Valabrega G; Powell MA; Hietanen S; Miller EM; Novak Z; Holloway R; Denschlag D; Myers T; Thijs AM; Pennington KP; Gilbert L; Fleming E; Zub O; Landrum LM; Ataseven B; Gogoi R; Podzielinski I; Cloven N; Monk BJ; Sharma S; Herzog TJ; Stuckey A; Pothuri B; Secord AA; Chase D; Vincent V; Meyers O; Garside J; Mirza MR; Black D
    Int J Gynecol Cancer; 2024 Sep; ():. PubMed ID: 39322611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment patterns and real-world clinical outcomes in patients with advanced endometrial cancer who are microsatellite instability (MSI)-high or are mismatch repair deficient (dMMR) in the United States.
    Kelkar SS; Prabhu VS; Corman S; Odak S; Rusibamayila N; Macahilig C; Orlowski R; Duska L
    Gynecol Oncol; 2023 Feb; 169():154-163. PubMed ID: 36344294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study.
    O'Malley DM; Bariani GM; Cassier PA; Marabelle A; Hansen AR; De Jesus Acosta A; Miller WH; Safra T; Italiano A; Mileshkin L; Xu L; Jin F; Norwood K; Maio M
    J Clin Oncol; 2022 Mar; 40(7):752-761. PubMed ID: 34990208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.